Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues ...
Asianet Newsable on MSN
Pfizer stock on-track for worst day in over 8 months as BofA flags faster Covid-19 product erosion
The company now expects full year 2025 guidance of about $62 billion, to the lower end of its previous guidance of $61 to $64 billion and below an analyst estimate of $62.52 billion.
Amid profit forecast reductions, Pfizer is implementing a $7.7bn cost-cutting strategy, while investing into its ...
Pfizer said on Tuesday the next few years will be bumpy, beginning with 2026, due to lower sales of its COVID vaccine and ...
Neoantigen vaccines are at the forefront of cancer research, driving personalized immunotherapy and improving outcomes ...
The UKHSA will carry out work to strengthen the UK’s pandemic preparedness, vaccine delivery and AMR response over the next ...
AI-driven research has produced nasal antivirals that block flu and Covid before cell infection, pointing to new prevention ...
A rapid, two-step immune reaction may underlie rare cases of heart inflammation seen after COVID-19 mRNA vaccination, ...
Researchers at the Icahn School of Medicine at Mount Sinai have developed a first-of-its-kind mRNA system that switches on therapeutic genes preferentially inside targeted cells—an advance ...
NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...
From vaccine hostility to the dismantling of USAID, the consequences of this year’s retrenchments will be felt for years to ...
The book traverses India’s active role in global vaccine research landscape from 1890s to 1940s; the next two decades—1950s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback